Assertio Holdings (ASRT) Stock Price

Assertio Holdings Price

NASDAQ·CLOSED
23.50
​
Market closed

Revenue has compounded at 14.2% per year over the past 19 years to 118.71 M USD. Earnings per share have declined at 6.0% per year over the last 15 years. Assertio Holdings's net margin stands at -25.6%, down from -1.2% several years earlier. Analysts set a median price target of 22.65 USD, implying 3.6% below the current price. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus.

Assertio Holdings stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Assertio Holdings business model & stock analysis

Assertio Holdings, Inc. generates revenue through the sale of prescription medications in neurology, inflammation, and pain management. Its marketed products include Cambia (diclofenac potassium) oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO tablets, SPRIX Nasal Spray, VIVLODEX capsules, ZIPSOR Liquid filled capsules, and ZORVOLEX capsules. These products are sold to healthcare providers and pharmacies within the U.S. market. The company also develops and commercializes pipeline products such as Diclofenac Potassium for mild/moderate acute pain, Long-acting Cosyntropin for adrenal insufficiency diagnosis, and a liquid formulation of Diclofenac potassium for acute migraine attacks, targeting specialty and orphan medicine segments. Assertio focuses on neurology, inflammation, and pain medication markets, with its portfolio primarily serving U.S. healthcare systems. The company's pipeline emphasizes specialty and orphan medicines, aiming to address unmet medical needs. Its revenue streams are derived from both existing marketed products and future commercialization of pipeline candidates, with a strategic emphasis on high-value therapeutic areas. The firm’s product lineup includes both established medications and emerging therapies, with Diclofenac Potassium appearing in multiple formulations across different therapeutic applications. This dual approach allows Assertio to maintain steady revenue from current sales while building toward future growth through its pipeline development efforts.

Frequently asked questions about Assertio Holdings

Analysts currently set an average price target of 22.65 USD for the Assertio Holdings stock (median: 22.65 USD), implying -3.6 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the Assertio Holdings stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Assertio Holdings to generate revenue of 116.70 M USD and earnings per share of -1.79 USD.

Converted at the current exchange rate, the Assertio Holdings share trades at 21.01 EUR (23.50 USD).

The Assertio Holdings share (ASRT) is listed on 1 stock exchanges, including: NASDAQ (ASRT).

The expected revenue of Assertio Holdings is 116.70 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Assertio Holdings is -11.49 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Assertio Holdings is currently -13.13. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Assertio Holdings stock.

The price-to-sales ratio (P/S) of Assertio Holdings is currently 1.29. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Assertio Holdings stock.

The Eulerpool Quality Score for Assertio Holdings is 1/10.

The ISIN of Assertio Holdings is US04546C3043. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Assertio Holdings is A2P4ZQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Assertio Holdings is ASRT. The ticker symbol is used to trade Assertio Holdings shares on the stock exchange.

Fair ValueTerminal
21.85 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
2.24 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Feb 12, 1997
ISIN
US04546C3043
Cusip
04546C106
Sedol
BMFYGV3
Market capitalization
150.87 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-13.13
P/Ee 2027
40.52
P/Ee 2028
13.66
P/Ee 2029
8.19
P/Ee 2030
6.22
P/S
P/Se
1.29
EV/EBIT
—
P/B Ratio
1.61
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-22.67 %
Last updated Nov 11, 2026, 5:45 AM

Assertio Holdings Ticker

NASDAQ · ASRT

All fundamentals and in-depth analysis of Assertio Holdings

Our stock analysis for Assertio Holdings stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Assertio Holdings. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.